Alliance Global Partners Maintains Buy on Tonix Pharmaceuticals, Lowers Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
Alliance Global Partners analyst James Molloy has maintained a 'Buy' rating on Tonix Pharmaceuticals (NASDAQ:TNXP), but lowered the price target from $18 to $8.
August 04, 2023 | 9:39 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Despite the lowered price target from $18 to $8, Alliance Global Partners maintains a 'Buy' rating on Tonix Pharmaceuticals.
The news is directly related to Tonix Pharmaceuticals and is likely to impact its stock. The 'Buy' rating indicates positive sentiment, but the lowered price target may cause some uncertainty among investors, potentially leading to short-term volatility in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100